Total Funding
49
60
Total FundingGrant raised
Growth Score 49 in past quarter
-8 pts
Heat Score 60 in past quarter
-5 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
86012
Amarna Therapeutics is a privately held European biotechnology company.
- Peter de Haan: Chief Scientific Officer & Co-founder
- Henk Johan Streefkerk: Chief Executive Officer
About the Company
Based on its unique properties SVac is ideally suited for developing next generation effective gene and immune-therapies. In order to realize our ambition to become the leading global gene therapy company they formed a worldwide consortium of key players in the virology, vector production, immunology, ophthalmology, oncology, neurology and gene
therapy fields of research. With major regulatory, legal and intellectual property firms, they are developing a range of innovative and effective interventions for genetic disorders, degenerative diseases, allergies and cancer. Interventions that will dramatically improve patients’ life expectancy and quality and moreover will significantly reduce the health care costs of the society in general.
